PUNE, India, November 11, 2016
PUNE, India, November 11, 2016 /PRNewswire/ --
ReportsnReports.com adds "Polycystic Kidney Disease - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Complete report on H2 2016 pipeline review of Polycystic Kidney Disease with 29 market data tables and 16 figures, spread across 87 pages is available at http://www.reportsnreports.com/reports/743483-polycystic-kidney-disease-pipeline-review-h2-2016.html.
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
Companies discussed in this Polycystic Kidney Disease Pipeline Review, H2 2016 report include Angion Biomedica Corp., Aptevo Therapeutics Inc, DiscoveryBiomed, Inc., Endocyte, Inc., IC-MedTech, Inc., Ipsen S.A. , Kadmon Corporation, LLC, ManRos Therapeutics, Metabolic Solutions Development Company, LLC, NovaTarg Therapeutics, Inc, Otsuka Holdings Co., Ltd. and XORTX Pharma Corp. Drug profiles mentioned in this research report are (ascorbic acid + menadione), ANG-3070, CIM-2, CR-8, DBM-43H11, Drugs for Polycystic Kidney Disease, EC-0371, JP-153, lanreotide acetate, menadione sodium bisulfite, MSDC-0160, MSDC-0602, oxypurinol, pyrimethamine, Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease, Small Molecules to Activate AMPK for Polycystic Kidney Disease, Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors, Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease, STA-2842, tesevatinib tosylate, TNFR x TWEAKR and tolvaptan.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=743483 .
The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 11 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Polycystic Kidney Disease.
Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Another newly published market research report titled on Kidney Transplant Rejection - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Kidney Transplant Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplant Rejection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alexion Pharmaceuticals Inc, Amgen Inc., Amyndas Pharmaceuticals LLC, Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Astellas Pharma Inc., Bio-inRen, Biogen Inc, Catalyst Biosciences, Inc., Corline Biomedical AB, CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A., Hansa Medical AB, Kyowa Hakko Kirin Co., Ltd., Mabtech Limited, Magnus Life Ltd, Noorik Biopharmaceuticals AG, Novartis AG, Opsona Therapeutics Limited, OSE Immunotherapeutics, Pharmicell Co., Ltd., Pharming Group N.V., Prolong Pharmaceuticals, LLC, Quark Pharmaceuticals, Inc., Shire Plc and Tiziana Life Sciences Plc. Kidney Transplant Rejection Pipeline market research report of 174 pages is available at http://www.reportsnreports.com/reports/743419-kidney-transplant-rejection-pipeline-review-h2-2016.html.
Explore more reports on Pharmaceuticals .
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd floor, metropole, Next to inox theatre, Bund garden road,
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
SOURCE ReportsnReportsPR Newswire
Last updated on: 11/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.